A composition of acylethanolamides is obtained from olive oil fatty acids and is used in treating neuroinflammation. The acylethanolamide complex includes (weight percentages):

TABLE-US-00001 oleoylethanolamide (OEA) C18:1 60-65%  palmitoylethanolamide (PEA) C16:0 5-20% linoleylethanolamide (LEA) C18:2 5-20% stearoylethanolamide (SEA) C18:0  1-2% palmitoylethanolamide (POEA) C16:1 0.1-0.8%  myristoylethanolamide (MEA) C14:0 0.02-0.15%   mixture of glycerides  4-6% glycerol .sup. 6-8%.

A method obtains the acylethanolamide complex and formulations contain the acylethanolamide complex.

A composition of acylethanolamides is obtained from olive oil fatty acids and is used in treating neuroinflammation. The acylethanolamide complex includes (weight percentages):

TABLE-US-00001 oleoylethanolamide (OEA) C18:1 60-65%  palmitoylethanolamide (PEA) C16:0 5-20% linoleylethanolamide (LEA) C18:2 5-20% stearoylethanolamide (SEA) C18:0  1-2% palmitoylethanolamide (POEA) C16:1 0.1-0.8%  myristoylethanolamide (MEA) C14:0 0.02-0.15%   mixture of glycerides  4-6% glycerol .sup. 6-8%.

A method obtains the acylethanolamide complex and formulations contain the acylethanolamide complex.

The invention provides a topical o/w emulsion which moisturizes, and protects, repairs or restores the skin lipid barrier of a mammal. The topical o/w emulsion composition comprises: a) a discontinuous oil phase; b) a continuous aqueous phase comprising water; c) a thickening agent; d) at least one lamellar membrane structure comprising (i) a phospholipid, (ii) a fatty alcohol, and (iii) a fatty acid; e) a pharmaceutically acceptable active agent; and f) optionally a dermatologically acceptable excipient. In one embodiment, the composition, in use, has a water vapor transmission rate of less than or about 75 g.Math.m.sup.−2.Math.hr.sup.−1 measured in vitro using the modWVTR test methodology.

The present invention relates to lyso-diacylglyceryltrimethylhomoserine (lyso-DGTS) or derivatives thereof for use in the treatment of atherosclerotic cardiovascular disease, and further provides particular such lyso-DGTS derivatives.

The present invention provides compositions comprising an active agent combination consisting of at least two of a cannabinoid, e.g., CBD, Dragon's blood, and palmitoylethanolamide (PEA), which is useful for treatment of inter alia inflammatory diseases or conditions of the skin; and methods of use.

The present invention provides compositions comprising an active agent combination consisting of at least two of a cannabinoid, e.g., CBD, Dragon's blood, and palmitoylethanolamide (PEA), which is useful for treatment of inter alia inflammatory diseases or conditions of the skin; and methods of use.

The present invention provides compositions comprising an active agent combination consisting of at least two of a cannabinoid, e.g., CBD, Dragon's blood, and palmitoylethanolamide (PEA), which is useful for treatment of inter alia inflammatory diseases or conditions of the skin; and methods of use.

Provided are compositions and methods comprising a sanshool for the treatment of obesity as part of a controlled diet regime in an individual. Also provided are compositions and methods comprising a sanshool for treatment of a smoking or vaping addiction. Suitably the compositions are applied topically to the lips of the individual in response to a habitual urge to consume food, smoke or vape as required.

Provided are compositions and methods comprising a sanshool for the treatment of obesity as part of a controlled diet regime in an individual. Also provided are compositions and methods comprising a sanshool for treatment of a smoking or vaping addiction. Suitably the compositions are applied topically to the lips of the individual in response to a habitual urge to consume food, smoke or vape as required.

Provided are compositions and methods comprising a sanshool for the treatment of obesity as part of a controlled diet regime in an individual. Also provided are compositions and methods comprising a sanshool for treatment of a smoking or vaping addiction. Suitably the compositions are applied topically to the lips of the individual in response to a habitual urge to consume food, smoke or vape as required.